Education

Ph.D. in University of Maryland Baltimore County

Current position

Oncomed Pharmaceuticals

Publications

1. Srivastava, M. K., Sinha, P., Clements, V. K., Rodriguez, P. and Ostrand-Rosenberg, S. (2010). Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res 70(1): 68-77.

2. Srivastava, M. K., Bosch, J. J., Wilson, A. L., Edelman, M. J. and Ostrand-Rosenberg, S. (2010). MHC II lung cancer vaccines prime and boost tumor-specific CD4+ T cells that cross-react with multiple histologic subtypes of nonsmall cell lung cancer cells. Int J Cancer 127(11): 2612-2621.

3. Bosch, J. J., Iheagwara, U. K., Reid, S., Srivastava, M. K., Wolf, J., Lotem, M., Ksander, B. R. and Ostrand-Rosenberg, S. (2010). Uveal melanoma cell-based vaccines express MHC II molecules that traffic via the endocytic and secretory pathways and activate CD8+ cytotoxic, tumor-specific T cells. Cancer Immunol Immunother 59(1): 103-112.

4. Srivastava, M. K., Bosch, J. J., Thompson, J. A., Ksander, B. R., Edelman, M. J. and Ostrand-Rosenberg, S. (2008). Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells. Cancer Immunol Immunother 57(10): 1493-1504.

5. Thompson, J. A., Srivastava, M. K., Bosch, J. J., Clements, V. K., Ksander, B. R. and Ostrand-Rosenberg, S. (2008). The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4+ T lymphocytes. Cancer Immunol Immunother 57(3): 389-398.

6. Bosch, J. J., Thompson, J. A., Srivastava, M. K., Iheagwara, U. K., Murray, T. G., Lotem, M., Ksander, B. R. and Ostrand-Rosenberg, S. (2007). MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells. Cancer Res 67(9): 4499-4506.